Kimberly L Spooner1, Samantha Fraser-Bell1,2,3, Thomas Hong1, James G Wong1,2,4, Andrew A Chang5,6. 1. Sydney Retina Clinic, Sydney, NSW, Australia. 2. Discipline of Ophthalmology, The University of Sydney, The Save Sight Institute, Sydney Medical School, Sydney, NSW, Australia. 3. Retina Associates, Sydney, NSW, Australia. 4. Strathfield Retina Clinic, Strathfield, NSW, Australia. 5. Sydney Retina Clinic, Sydney, NSW, Australia. achang@sydneyretina.com.au. 6. Discipline of Ophthalmology, The University of Sydney, The Save Sight Institute, Sydney Medical School, Sydney, NSW, Australia. achang@sydneyretina.com.au.
Abstract
BACKGROUND/ OBJECTIVES: To analyze the long-term outcomes of eyes with retinal vein occlusion (RVO) 8 years after commencing treatment with anti-vascular endothelial growth factor (VEGF) agents. SUBJECTS/ METHODS: Retrospective, multicentre study of 221 eyes diagnosed with RVO, which were commenced on anti-VEGF therapy between 2009 and 2011. VA and CRT were recorded at baseline and at subsequent annual time points. The mean number of injections administered each year and the incidence of adverse events were recorded. RESULTS: Of a total of 221 eyes which commenced treatment with anti-VEGF agents for RVO, 95 were diagnosed with BRVO and 126 with CRVO. 8-year data were available for 94 eyes (43%). The mean age of patients was 65.1 ± 12.0 years. Mean VA improved from baseline by 16.9 letters, (57.8-74.7 letters), (P < 0.001). For BRVO eyes, mean VA improved from 60.5 to 74.8 letters (p < 0.001) and for CRVO eyes from 52.0 to 66.4 letters (p < 0.001). In all RVO eyes, there was a reduction in mean CRT from 501.0 to 249.1 µm; in BRVO eyes from 472.4 to 284.7 µm and in CRVO eyes from 533.9 to 267.5 µm. In the 8th year after starting treatment, eyes with RVO were receiving a mean of four injections. CONCLUSION: Good long-term outcomes of VEGF inhibition for eyes with RVO were found in this study. Patients maintained a gain of 3-lines of vision 8-years after the commencing therapy. This encouraging result contrasts with long-term studies of patients with neovascular age-related macular degeneration, where initial gains are lost over time.
BACKGROUND/ OBJECTIVES: To analyze the long-term outcomes of eyes with retinal vein occlusion (RVO) 8 years after commencing treatment with anti-vascular endothelial growth factor (VEGF) agents. SUBJECTS/ METHODS: Retrospective, multicentre study of 221 eyes diagnosed with RVO, which were commenced on anti-VEGF therapy between 2009 and 2011. VA and CRT were recorded at baseline and at subsequent annual time points. The mean number of injections administered each year and the incidence of adverse events were recorded. RESULTS: Of a total of 221 eyes which commenced treatment with anti-VEGF agents for RVO, 95 were diagnosed with BRVO and 126 with CRVO. 8-year data were available for 94 eyes (43%). The mean age of patients was 65.1 ± 12.0 years. Mean VA improved from baseline by 16.9 letters, (57.8-74.7 letters), (P < 0.001). For BRVO eyes, mean VA improved from 60.5 to 74.8 letters (p < 0.001) and for CRVO eyes from 52.0 to 66.4 letters (p < 0.001). In all RVO eyes, there was a reduction in mean CRT from 501.0 to 249.1 µm; in BRVO eyes from 472.4 to 284.7 µm and in CRVO eyes from 533.9 to 267.5 µm. In the 8th year after starting treatment, eyes with RVO were receiving a mean of four injections. CONCLUSION: Good long-term outcomes of VEGF inhibition for eyes with RVO were found in this study. Patients maintained a gain of 3-lines of vision 8-years after the commencing therapy. This encouraging result contrasts with long-term studies of patients with neovascular age-related macular degeneration, where initial gains are lost over time.
Authors: Rohit Varma; Neil M Bressler; Ivan Suñer; Paul Lee; Chantal M Dolan; James Ward; Shoshana Colman; Roman G Rubio Journal: Ophthalmology Date: 2012-07-18 Impact factor: 12.079
Authors: Sophie L Rogers; Rachel L McIntosh; Lyndell Lim; Paul Mitchell; Ning Cheung; Jonathan W Kowalski; Hiep P Nguyen; Jie Jin Wang; Tien Yin Wong Journal: Ophthalmology Date: 2010-06 Impact factor: 12.079
Authors: Mark Gillies; Jennifer Arnold; Sanjeeb Bhandari; Rohan W Essex; Stephanie Young; David Squirrell; Vuong Nguyen; Daniel Barthelmes Journal: Am J Ophthalmol Date: 2019-10-10 Impact factor: 5.258
Authors: Maureen G Maguire; Daniel F Martin; Gui-Shuang Ying; Glenn J Jaffe; Ebenezer Daniel; Juan E Grunwald; Cynthia A Toth; Frederick L Ferris; Stuart L Fine Journal: Ophthalmology Date: 2016-05-02 Impact factor: 12.079
Authors: Sophie Rogers; Rachel L McIntosh; Ning Cheung; Lyndell Lim; Jie Jin Wang; Paul Mitchell; Jonathan W Kowalski; Hiep Nguyen; Tien Y Wong Journal: Ophthalmology Date: 2010-02 Impact factor: 12.079
Authors: Jeffrey S Heier; W Lloyd Clark; David S Boyer; David M Brown; Robert Vitti; Alyson J Berliner; Husain Kazmi; Yu Ma; Brigitte Stemper; Oliver Zeitz; Rupert Sandbrink; Julia A Haller Journal: Ophthalmology Date: 2014-03-27 Impact factor: 12.079